Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 79-84

  Rajappa, Senthil ^a   Mallavarapu, Krishna Mohan ^a   Gundeti, Sadashivudu ^a   Roshnipaul, Tara ^a   Jacob, Rachel Thomas ^a   Digumarti, Raghunadharao ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytogenetic response; Dose escalation; Imatinib resistance; Kinase domain mutations

Indexed keywords

IMATINIB; PHOSPHOTRANSFERASE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 74949086656     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903437629     Document Type: Article

References (21)

1. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112: Abstract 186.
2. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Leukemia Net. Blood 2006;108:1809-1820.
3. National Comprehensive Cancer Network CML Guidelines V.2.2010; Available from: www.nccn.org [cited 25 August 2009].
4. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
5. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leukemia 2002;16:2190-2196.
6. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through bcr abl independence in chronic myeloid leukemia. Cancer Res 2004;64:672-677.
7. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR ABL kinase domain mutations confer polyclonal resistance to tyrosine kinase inhibitor imatinib mesylate in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
8. Willis S, Lange T, Demehri S, et al. High sensitivity detection of BCR ABL kinase domain mutations in imatinib naive patients: correlation with clonal cytogenetic evolution but not with response to therapy. Blood 2005;106:2128-2137.
9. Zonder JA, Pemberton P, Brandt H, Mohmad AN, Schiffer CA. The effect of dose increase to imatinib mesylate with chronic or accelerated phase chronic myeloid leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2002;9:2092-2097.
10. Marin D, Goldman JM, Olavarria E, Apperly J. Transient benefit only from increasing the matinib dose in CML patients who do not achieve cytogenetic remissions on conventional doses. Blood 2003;102:2702-2703.
11. Kantarjian H, Talpaz M, O Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475. (Pubitemid 36077567)
12. Jabbour E, Kantarjian M, Jones D, et al. Imatinib dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard dose imatinib therapy. Blood 2009;113:2154-2160.
13. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150. (Pubitemid 46890528)
14. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of BCR ABL tyrosine kinase in chronic myeloid leukemia. New Eng J Med 2001;334:1031-1037.
15. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937. (Pubitemid 34525471)
16. Hochhaus A, La Rosee P. Imatinib therapy in chronic myeloid leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321-1331.
17. Kantarjian H, Sawers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Eng J Med 2002;346:645-652.
18. O'Hare T, Eide C, Deninger M, et al. BCR ABL kinase domain mutations, drug resistance and the road to a cure for chronic myeloid leukemia. Blood 2007;110: 2242-2249.
19. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-1773. (Pubitemid 44574988)
20. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR ABL mutations in patients with CML is virtually always accompanied by clinical resistance and mutations in the ATP phosphate binding loop (P-loop) are associated with poor prognosis. Blood 2003;102:276-283.
21. Kantarjian H, Rousselot P, Pasquini R, et al. Dasatinib or high dose imatinib for patients with chronic phase chronic myeloid leukemia resistant to standard dose imatinib: a 2 year follow up from the START-R (CA-180-017). Blood 2007;110 (Suppl.):226a (Abstract 736).